FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Russell Schilder

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Treatment Outcome

Phenomena

Recurrence

Physiology

Anatomy

Chromosomes, Human, Pair 9

Co-author Network

Publications

TOP 3
Katherine Marie Bell-McGuinn; Carolyn M Matthews; Steffan N Ho; Minal Barve; Lucy Gilbert; Richard T Penson; Ernst Lengyel; Rameshraja Palaparthy; Kye Gilder; Artemios Vassos; William McAuliffe; Sara Weymer; Jeremy Barton; Russell J Schilder
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.
Carol Aghajanian; John A Blessing; Kathleen M Darcy; Gary Reid; Koen DeGeest; Stephen C Rubin; Robert S Mannel; Jacob Rotmensch; Russell J Schilder; William Riordan
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Jason Konner; Russell J Schilder; Felicia A DeRosa; Scott Gerst; William P Tew; Paul Sabbatini; Martee Hensley; David Spriggs; Carol Aghajanian
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Russell Schilder (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Katherine Marie Bell-McGuinn; Carolyn M Matthews; Steffan N Ho; Minal Barve; Lucy Gilbert; Richard T Penson; Ernst Lengyel; Rameshraja Palaparthy; Kye Gilder; Artemios Vassos; William McAuliffe; Sara Weymer; Jeremy Barton; Russell J Schilder
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.
Gynecologic oncology 2011;121(2):273-9.
2009: Carol Aghajanian; John A Blessing; Kathleen M Darcy; Gary Reid; Koen DeGeest; Stephen C Rubin; Robert S Mannel; Jacob Rotmensch; Russell J Schilder; William Riordan
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Gynecologic oncology 2009;115(2):215-20.
2008: Jason Konner; Russell J Schilder; Felicia A DeRosa; Scott Gerst; William P Tew; Paul Sabbatini; Martee Hensley; David Spriggs; Carol Aghajanian
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
Gynecologic oncology 2008;110(2):140-5.
2007: Christos Emmanouilides; Thomas E Witzig; Gregory A Wiseman; Leo I Gordon; Hua Wang; Russell J Schilder; M Wayne Saville; Ian W Flinn; Arturo Molina
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.
Cancer biotherapy & radiopharmaceuticals 2007;22(5):684-91.
2007: Gregory A Wiseman; Peter S Conti; Katie Vo; Russell J Schilder; Leo I Gordon; Christos Emmanouilides; Daniel H S Silverman; Thomas E Witzig; Mohamed Darif; Arturo Molina
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Clinical lymphoma & myeloma 2007;7(8):514-7.
2007: Susan O'Brien; Ellin Berman; Kapil N Bhalla; Edward A Copelan; Marcel P Devetten; Peter D Emanuel; Harry P Erba; Peter L Greenberg; Joseph O Moore; Donna Przepiorka; Jerald P Radich; Russell J Schilder; Paul Shami; B Douglas Smith; David S Snyder; Robert J Soiffer; Martin S Tallman; Moshe Talpaz; Meir Wetzler
Chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(5):474-96.
2007: Thomas E Witzig; Arturo Molina; Leo I Gordon; Christos Emmanouilides; Russell J Schilder; Ian W Flinn; Mohamed Darif; Roger M Macklis; Katie Vo; Gregory A Wiseman
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
Cancer 2007;109(9):1804-10.
2006: Christos Emmanouilides; Thomas E Witzig; Leo I Gordon; Katie Vo; Gregory A Wiseman; Ian W Flinn; Mohamed Darif; Russell J Schilder; Arturo Molina
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
Leukemia & lymphoma 2006;47(4):629-36.
2006: Richard T Hoppe; Ranjana Advani; Philip J Bierman; Clara D Bloomfield; Francis Buadi; Benjamin Djulgegovic; Andres Forero; Leo I Gordon; Francisco J Hernandez-Ilizaliturri; Mark S Kaminski; Gena Love; David G Maloney; Peter M Mauch; Joseph O Moore; Russell J Schilder; Lawrence Weiss; Jane N Winter; Joachim Yahalom; Andrew D Zelenetz
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(3):210-30.
2005: Susan O'Brien; Ellin Berman; Kapil N Bhalla; Edward A Copelan; Marcel P Devetten; Peter D Emanuel; Harry P Erba; Peter L Greenberg; Joseph O Moore; Donna Przepiorka; Jerald P Radich; Russell J Schilder; Paul Shami; B Douglas Smith; David S Snyder; Robert J Soiffer; Martin S Tallman; Moshe Talpaz; Meir Wetzler
Chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(6):732-55.
2004: Stephen M Ansell; Russell J Schilder; Peter C Pieslor; Leo I Gordon; Christos Emmanouilides; Katie Vo; Myron S Czuczman; Thomas E Witzig; Charles Theuer; Arturo Molina
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
Clinical lymphoma 2004;5(3):202-4.
2004: Russell J Schilder; Arturo Molina; Nancy L Bartlett; Thomas E Witzig; Leo Gordon; James Murray; Stewart Spies; Hua Wang; Gregory A Wiseman; Christine White
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Cancer biotherapy & radiopharmaceuticals 2004;19(4):478-81.
2004: Leo I Gordon; Arturo Molina; Thomas E Witzig; Christos Emmanouilides; Andrew Raubtischek; Mohamed Darif; Russell J Schilder; Gregory A Wiseman; Christine White
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.
Blood 2004;103(12):4429-31.
2003: Gregory A Wiseman; Bryan R Leigh; William D Erwin; Richard B Sparks; Donald A Podoloff; Russell J Schilder; Nancy L Bartlett; Stewart M Spies; Antonio J Grillo-López; Thomas E Witzig; Christine White
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
Cancer biotherapy & radiopharmaceuticals 2003;18(2):165-78.
2002: Gregory A Wiseman; Leo I Gordon; Pratik Multani; Thomas E Witzig; Stewart Spies; Nancy L Bartlett; Russell J Schilder; James L Murray; Mansoor Saleh; Roberta S Allen; Antonio J Grillo-López; Christine White
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
Blood 2002;99(12):4336-42.
2000: Ellin Berman; Reginald Clift; Edward A Copelan; Peter D Emanuel; Harry P Erba; MJ Glenn; Peter L Greenberg; Richard J Jones; S O'Brien; Hussain I Saba; Russell J Schilder; D S Snyder; Robert J Soiffer; Martin S Tallman; M Wetzler; F Ravandi-Kashani; Andrew Lamb; Moshe Talpaz
NCCN Practice Guidelines for Chronic Myelogenous Leukemia.
Oncology (Williston Park, N.Y.) 2000;14(11A):229-40.
1999: Thomas E Witzig; Christine White; Gregory A Wiseman; Leo I Gordon; Christos Emmanouilides; A Raubitschek; N Janakiraman; John C Gutheil; Russell J Schilder; Stewart Spies; Daniel H S Silverman; E Parker; Antonio J Grillo-López
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(12):3793-803.
1999: Gregory A Wiseman; Christine White; Thomas E Witzig; Leo I Gordon; Christos Emmanouilides; A Raubitschek; N Janakiraman; John C Gutheil; Russell J Schilder; Stewart Spies; Daniel H S Silverman; Antonio J Grillo-López
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3281s-3286s.
1997: DG Maloney; Antonio J Grillo-López; Christine White; D Bodkin; Russell J Schilder; J A Neidhart; N Janakiraman; K A Foon; Tina Marie Liles; BK Dallaire; K Wey; I Royston; T Davis; Ronald Levy
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
Blood 1997;90(6):2188-95.
1996: Leo I Gordon; J Anderson; T M Habermann; J N Winter; J Glick; Russell J Schilder; Peter A Cassileth
Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1275-81.